Solutions

RxScorecard™

Unique insight into assessing drug value

RxScorecard offers the first and only tool to assess the value of marketed and pipeline drugs from a payer’s point of view. Faced with increasing market access challenges, manufacturers must strengthen value differentiation for new drugs from a payer perspective to obtain favorable reimbursement. Payers seek an objective, transparent tool to help assess the relative value of emerging and existing therapies, and inform formulary and UM policies.

RxScorecard Mock-up

Evidence-based and fully transparent
Comprehensive and built at the sub-population level
Updated to reflect new data
Scenario builder models future data and market shifts
Reflects value for different stakeholders
Customized

COPD: Gold Stages 3 & 4

Note: Weightings reflect payer viewpoint; illustrative example for one COPD drug.

Clinical Efficacy

Domain Weight 40%

Element	Weighted Score
Forced Expiratory Volume in One Second (FEV1)	2.7
Exacerbation	8.5
Lung Function Rate of Decline	0.0

Safety and Use

Domain Weight 30%

Element	Weighted Score
Adherence (Convenience)	5.0
Adherence (Discontinuation Rate)	2.5
Adherence (Route of Administration)	5.0
Monitoring	2.5
Adverse Events (Overall)	4.5
Targeting	0.0

Economics

Domain Weight 30%

Element	Weighted Score
Price per Average Course of Therapy	6.3
Near-Term Market Competition	1.9
Potential for Off-Label and Unproven Use	2.5
Costs Offsets	0.7
Switching Costs	2.0

MANUFACTURERS use RxScorecard to:

Inform value-based contracts
Guide evidence generation and prioritize sub-populations
Identify go/no-go thresholds
Benchmark opportunities across countries
Assess payer perspective by segment
Align internal stakeholders

PAYERS use RxScorecard to:

Inform value-based contracts
Assess value of emerging drugs via a systematic comparative review
Provide P&T with transparent, objective drug assessments
Inform formulary policy and utilization management decisions

Featured Case Study

Situation

Biotechnology company with an early phase drug sought to challenge an entrenched competitor

Approach

Leveraged RxScorecard to assess value of client’s asset vs. leading competitor across several sub-populations

Findings

Range of findings around relative differentiation by subpopulation, the influence of different drug attributes, development gaps, etc.
In the chronic kidney disease (CKD) population, standard-of care (SOC) Drug A scores substantially worse vs. New Drug B on four safety elements
As a result, the value of New Drug B was substantially differentiated vs. the incumbent in the CKD sub-population

Example: Population with Chronic Kidney Disease (CKD)

Example: Population with Chronic Kidney Disease (CKD)

Solution

Client is overhauling development plans and market approach to address identified opportunities.

Client is incorporating RE’s input into ongoing partnership discussions.

RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.

Chronis H. Manolis, RPh

Vice President, Pharmacy UPMC Health Plan

RxScorecard lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment.

Ammar Qadan

Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.

We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.

Jack Bailey

President , GlaxoSmithKline U.S.

With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard becomes even more important.

Michael S. Sherman, MD, MBA

Senior Vice President and Chief Medical Officer, Harvard Pilgrim Health Care